Some of the immunohistochemical markers have also been previously tested in malignant and premalignant stages of colorectal and gastroesophageal cancers.38, 39 The combination of CDH17 and CLDN18, for example, has been confirmed as being predictive for nodal involvement and poor prognosis in gastric adenocarcinomas.40 CLDN18 is a dominant marker in our poor prognosis Group 1 and CDH17 is characteristic for Group 2 which shows intermediate outcome in our primary cohort, but poor prognosis in some of the validation cohort. Here, CLDN18 is linked to gastric adenocarcinoma.